tradingkey.logo
tradingkey.logo
Search

Inhibrx Biosciences Inc

INBX
Add to Watchlist
82.050USD
-2.680-3.16%
Close 07-31 16:00ETQuotes delayed by 15 min
1.20BMarket Cap
LossP/E TTM

INBX Income Statement

You can find the annual or quarterly income statement of Inhibrx Biosciences Inc here for insights into the performance and operational efficiency of Inhibrx Biosciences Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
FY2019Q2
FY2019Q1
FY2018Q4
FY2018Q3
FY2018Q2
FY2018Q1
Total revenue
----
-100.00%0.00
--0.00
1200.00%1.30M
----
-93.88%100.00K
-100.00%0.00
233.33%100.00K
-100.00%0.00
496.35%1.63M
-57.19%119.00K
-95.78%30.00K
-98.17%17.00K
-90.41%274.00K
-89.02%278.00K
-25.47%711.00K
4.50%929.00K
2.88%2.86M
-57.09%2.53M
-71.43%954.00K
1.95%889.00K
--2.78M
--5.90M
4.05%3.34M
-89.77%872.00K
14.16%3.21M
205.05%8.52M
--2.27M
--722.00K
--2.81M
--2.79M
Revenue
----
-100.00%0.00
----
1200.00%1.30M
----
-93.88%100.00K
-100.00%0.00
233.33%100.00K
----
496.35%1.63M
-57.19%119.00K
-95.78%30.00K
-98.17%17.00K
-90.41%274.00K
-89.02%278.00K
-25.47%711.00K
4.50%929.00K
2.88%2.86M
-57.09%2.53M
-71.43%954.00K
1.95%889.00K
--2.78M
--5.90M
4.05%3.34M
-89.77%872.00K
14.16%3.21M
205.05%8.52M
--2.27M
--722.00K
--2.81M
--2.79M
Operating expenses
-27.91%30.93M
-38.19%30.92M
-27.75%33.81M
-82.18%28.69M
-41.89%42.90M
-44.37%50.03M
1.85%46.80M
289.18%161.00M
68.62%73.83M
151.36%89.92M
51.73%45.95M
17.17%41.37M
46.21%43.78M
60.71%35.77M
41.94%30.28M
70.12%35.31M
53.99%29.95M
11.95%22.26M
-0.59%21.33M
1.21%20.75M
5.22%19.45M
--19.88M
--21.46M
48.49%20.51M
52.35%18.48M
45.61%13.81M
3.78%12.13M
--6.35M
--10.58M
--9.48M
--11.69M
R&D expenses
-31.97%24.69M
-26.25%24.17M
-26.87%27.96M
-67.76%21.68M
-42.94%36.29M
-59.95%32.78M
1.16%38.23M
98.61%67.26M
71.19%63.59M
170.95%81.84M
53.13%37.80M
14.18%33.86M
50.79%37.15M
62.26%30.20M
33.53%24.68M
65.67%29.66M
49.88%24.64M
5.36%18.61M
-6.82%18.48M
-5.65%17.90M
-3.40%16.44M
--17.67M
--19.84M
55.86%18.97M
59.55%17.02M
43.31%12.17M
-1.06%10.66M
--4.68M
--9.50M
--8.49M
--10.78M
Depreciation, depletion, and amortization
-20.44%537.00K
71.99%1.19M
-23.29%583.00K
39.08%662.00K
87.50%675.00K
131.21%689.00K
150.00%760.00K
61.36%476.00K
22.03%360.00K
-1.32%298.00K
-1.62%304.00K
-3.91%295.00K
-3.91%295.00K
-1.63%302.00K
3.34%309.00K
3.02%307.00K
5.50%307.00K
15.85%307.00K
20.08%299.00K
19.68%298.00K
13.67%291.00K
--265.00K
--249.00K
17.45%249.00K
33.33%256.00K
28.48%212.00K
27.15%192.00K
--199.00K
--161.00K
--165.00K
--151.00K
Operating profit
27.91%-30.93M
38.06%-30.92M
27.75%-33.81M
82.98%-27.39M
41.89%-42.90M
43.45%-49.93M
-2.12%-46.80M
-289.22%-160.90M
-68.68%-73.83M
-148.70%-88.29M
-52.74%-45.83M
-19.49%-41.34M
-50.83%-43.77M
-82.95%-35.50M
-59.58%-30.00M
-74.72%-34.60M
-56.36%-29.02M
-13.43%-19.40M
-20.84%-18.80M
-15.34%-19.80M
-5.38%-18.56M
---17.11M
---15.56M
-61.94%-17.17M
-387.57%-17.61M
-58.86%-10.60M
59.40%-3.61M
---4.08M
---9.86M
---6.67M
---8.90M
Net non-operating interest income (expenses)
Non-operating interest income
-56.76%1.01M
-34.45%1.31M
-38.35%1.78M
-22.51%2.12M
-29.51%2.33M
-57.35%2.00M
24.44%2.89M
13.55%2.74M
--3.30M
--4.70M
--2.32M
--2.41M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Non-operating interest expense
30.49%3.51M
--3.19M
--3.18M
-41.41%3.14M
-66.92%2.69M
-100.00%0.00
-100.00%0.00
-32.18%5.36M
60.04%8.13M
53.84%8.22M
52.60%8.15M
151.11%7.91M
123.39%5.08M
200.45%5.34M
200.34%5.34M
244.42%3.15M
205.23%2.27M
234.40%1.78M
-59.85%1.78M
-73.16%914.00K
-69.60%745.00K
--532.00K
--4.43M
594.90%3.41M
892.31%2.45M
26.29%490.00K
-45.23%247.00K
--297.00K
--344.00K
--388.00K
--451.00K
Special income (expenses)
----
--0.00
--0.00
-100.00%0.00
----
--0.00
--0.00
--2.02B
----
----
----
----
----
----
----
----
----
--0.00
100.00%0.00
-100.00%0.00
100.00%0.00
--0.00
---24.00K
--2.69M
---41.00K
----
--0.00
----
----
----
----
Other non-operating income (expenses)
76.00%-12.00K
-165.00%-39.00K
-212.20%-46.00K
-845.45%-246.00K
15.25%-50.00K
137.97%60.00K
130.37%41.00K
115.21%33.00K
15.71%-59.00K
-122.54%-158.00K
-850.00%-135.00K
-1376.47%-217.00K
-289.19%-70.00K
-1083.33%-71.00K
1900.00%18.00K
240.00%17.00K
131.25%37.00K
14.29%-6.00K
---1.00K
200.00%5.00K
60.00%16.00K
---7.00K
--0.00
-225.00%-5.00K
-16.67%10.00K
-66.67%4.00K
-57.14%12.00K
--14.00K
--14.00K
--12.00K
--28.00K
Income before tax
22.79%-33.44M
31.40%-32.83M
19.62%-35.26M
-101.54%-28.65M
44.97%-43.31M
47.96%-47.87M
15.30%-43.86M
4049.27%1.86B
-60.91%-78.71M
-124.79%-91.97M
-46.60%-51.79M
-24.70%-47.05M
-56.51%-48.92M
-93.10%-40.92M
-71.65%-35.33M
-82.17%-37.73M
-62.05%-31.25M
-20.08%-21.19M
-2.85%-20.58M
-15.80%-20.71M
4.01%-19.29M
---17.65M
---20.01M
-61.32%-17.89M
-422.30%-20.09M
-57.28%-11.09M
58.72%-3.85M
---4.37M
---10.19M
---7.05M
---9.32M
Income tax
--0.00
--0.00
--0.00
0.00%2.00K
--0.00
100.00%0.00
-100.00%0.00
-60.00%2.00K
----
-300.00%-4.00K
--2.00K
25.00%5.00K
--0.00
---1.00K
--0.00
--4.00K
-100.00%0.00
-100.00%0.00
--0.00
--0.00
--2.00K
--3.00K
--0.00
100.00%0.00
--0.00
---2.00K
--0.00
--46.00K
--50.00K
--0.00
--0.00
Equity earnings after tax
----
----
----
----
----
----
----
----
----
---1.63M
----
----
----
----
----
----
----
--0.00
100.00%0.00
----
----
--0.00
---487.00K
----
----
----
----
----
----
----
----
Income after tax
22.79%-33.44M
31.40%-32.83M
19.62%-35.26M
-101.54%-28.65M
44.97%-43.31M
47.96%-47.87M
15.30%-43.86M
4048.85%1.86B
-60.91%-78.71M
-124.78%-91.97M
-46.61%-51.79M
-24.70%-47.05M
-56.51%-48.92M
-93.10%-40.91M
-71.65%-35.33M
-82.19%-37.73M
-62.03%-31.25M
-20.06%-21.19M
-2.85%-20.58M
-15.80%-20.71M
4.00%-19.29M
---17.65M
---20.01M
-61.34%-17.89M
-422.30%-20.09M
-57.26%-11.09M
58.72%-3.85M
---4.41M
---10.24M
---7.05M
---9.32M
Net income from continuous operations
22.79%-33.44M
31.40%-32.83M
19.62%-35.26M
-101.54%-28.65M
44.97%-43.31M
48.86%-47.87M
15.30%-43.86M
4048.85%1.86B
-60.91%-78.71M
-128.78%-93.60M
-46.61%-51.79M
-24.70%-47.05M
-56.51%-48.92M
-93.10%-40.91M
-71.65%-35.33M
-82.19%-37.73M
-62.03%-31.25M
-20.06%-21.19M
-0.40%-20.58M
-15.80%-20.71M
4.00%-19.29M
---17.65M
---20.50M
-61.34%-17.89M
-422.30%-20.09M
-57.26%-11.09M
58.72%-3.85M
---4.41M
---10.24M
---7.05M
---9.32M
Net Income attributable to non-controlling interests
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
100.00%0.00
100.00%0.00
--0.00
--0.00
---142.00K
---453.00K
Net income attributable to controlling interests
22.79%-33.44M
31.40%-32.83M
19.62%-35.26M
-101.54%-28.65M
44.97%-43.31M
48.86%-47.87M
15.30%-43.86M
4048.85%1.86B
-60.91%-78.71M
-128.78%-93.60M
-46.61%-51.79M
-24.70%-47.05M
-56.51%-48.92M
-93.10%-40.91M
-71.65%-35.33M
-82.19%-37.73M
-62.03%-31.25M
-20.06%-21.19M
-0.40%-20.58M
-15.80%-20.71M
4.00%-19.29M
---17.65M
---20.50M
-61.34%-17.89M
-422.30%-20.09M
-54.90%-11.09M
58.88%-3.85M
---4.41M
---10.24M
---7.16M
---9.36M
Net income attributable to common shareholders
22.79%-33.44M
31.40%-32.83M
19.62%-35.26M
-101.54%-28.65M
44.97%-43.31M
48.86%-47.87M
15.30%-43.86M
4048.85%1.86B
-60.91%-78.71M
-128.78%-93.60M
-46.61%-51.79M
-24.70%-47.05M
-56.51%-48.92M
-93.10%-40.91M
-71.65%-35.33M
-82.19%-37.73M
-62.03%-31.25M
-20.06%-21.19M
-0.40%-20.58M
-15.80%-20.71M
4.00%-19.29M
---17.65M
---20.50M
-61.34%-17.89M
-422.30%-20.09M
-54.90%-11.09M
58.88%-3.85M
---4.41M
---10.24M
---7.16M
---9.36M
Basic earnings per share
23.37%-2.15
31.67%-2.11
19.68%-2.28
-101.46%-1.85
-94.07%-2.80
-78.82%-3.09
-158.18%-2.84
11888.42%127.10
-28.53%-1.44
-83.08%-1.73
-21.48%-1.10
-11.55%-1.08
-40.14%-1.12
-72.06%-0.94
-66.47%-0.90
-76.52%-0.97
-56.71%-0.80
-17.36%-0.55
0.08%-0.54
-12.23%-0.55
6.74%-0.51
---0.47
---0.54
-61.35%-0.49
-422.29%-0.55
-54.90%-0.30
58.88%-0.10
---0.12
---0.28
---0.20
---0.26
Diluted earnings per share
23.37%-2.15
31.67%-2.11
19.68%-2.28
-101.48%-1.85
-94.07%-2.80
-78.82%-3.09
-158.18%-2.84
11738.74%125.48
-28.53%-1.44
-83.08%-1.73
-21.48%-1.10
-11.55%-1.08
-40.14%-1.12
-72.06%-0.94
-66.47%-0.90
-76.52%-0.97
-56.71%-0.80
-17.36%-0.55
0.08%-0.54
-12.23%-0.55
6.74%-0.51
---0.47
---0.54
-61.35%-0.49
-422.29%-0.55
-54.90%-0.30
58.88%-0.10
---0.12
---0.28
---0.20
---0.26
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Inhibrx Biosciences Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing INBX stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Inhibrx Biosciences Inc's revenue at year end?

Inhibrx Biosciences Inc reported 1.30M in revenue for fiscal year 2025, up from 200.00K in the previous year.

What was Inhibrx Biosciences Inc's net income for the year?

Inhibrx Biosciences Inc posted -140.06M in net income for fiscal year 2025.

How much net income did Inhibrx Biosciences Inc post in the last quarter?

Inhibrx Biosciences Inc reported -33.44M in net income for the latest quarter。

What was Inhibrx Biosciences Inc's annual operating profit?

Inhibrx Biosciences Inc's operating income was -135.03M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.